Table 1.
Baseline Characteristics by Human Immunodeficiency Virus Status and Receipt of Tenofovir
| Characteristic | Patients, No. (%)a | |||||
|---|---|---|---|---|---|---|
| HIV Status in Full Cohort | Use of ART With Tenofovir in PWH | Use of HIV PrEP in PWoH (Subsetb) | ||||
| PWH | PWoH | Yes | No | Yes | No | |
| (n = 1785) | (n = 189 351) | (n = 1139) | (n = 646) | (n = 459) | (n = 173 921) | |
| Age, y | ||||||
| 18–29 | 99 (6) | 43 639 (23) | 70 (6) | 29 (4) | 135 (29) | 41 252 (24) |
| 30–39 | 299 (17) | 40 006 (21) | 206 (18) | 93 (14) | 171 (37) | 37 750 (22) |
| 40–49 | 314 (18) | 36 753 (19) | 206 (18) | 108 (17) | 89 (19) | 34 191 (20) |
| 50–59 | 524 (29) | 35 345 (19) | 345 (30) | 179 (28) | 51 (11) | 32 258 (19) |
| 60–69 | 387 (22) | 22 958 (12) | 228 (20) | 159 (25) | 13 (3) | 19 860 (11) |
| 70–79 | 162 (9) | 10 650 (6) | 84 (7) | 78 (12) | 0 (0) | 8610 (5) |
| Race/ethnicity | ||||||
| Non-Hispanic white | 441 (25) | 59 115 (31) | 294 (26) | 147 (23) | 154 (34) | 51 221 (29) |
| Non-Hispanic black | 829 (46) | 26 106 (14) | 493 (43) | 336 (52) | 62 (14) | 21 959 (13) |
| Hispanic | 332 (19) | 62 548 (33) | 234 (21) | 98 (15) | 154 (34) | 61 474 (35) |
| Asian | 25 (1) | 20 270 (11) | 19 (2) | 6 (1) | 53 (12) | 20 216 (12) |
| Other | 128 (7) | 6383 (3) | 86 (8) | 42 (7) | 10 (2) | 4164 (2) |
| Unknown | 30 (2) | 14 929 (8) | 13 (1) | 17 (3) | 26 (6) | 14 887 (9) |
| Male | 1541 (86) | 87 379 (46) | 987 (87) | 554 (86) | 429 (93) | 79 803 (46) |
| BMIc | ||||||
| Underweight | 25 (1) | 1330 (1) | 11 (1) | 14 (2) | 3 (1) | 1264 (1) |
| Normal | 361 (20) | 31 033 (16) | 216 (19) | 145 (22) | 133 (29) | 30 029 (17) |
| Overweight | 617 (35) | 49 942 (26) | 384 (34) | 233 (36) | 162 (35) | 48 234 (28) |
| Obese | 673 (38) | 73 623 (39) | 457 (40) | 216 (33) | 129 (28) | 70 676 (41) |
| Unknown | 109 (6) | 33 423 (18) | 71 (6) | 38 (6) | 32 (7) | 23 718 (14) |
| Smoking status | ||||||
| Current smoker | 434 (24) | 9870 (5) | 264 (23) | 170 (26) | 32 (7) | 8351 (5) |
| Former smoker | 442 (25) | 38 729 (20) | 281 (25) | 161 (25) | 113 (25) | 35 567 (20) |
| No history of smoking | 894 (50) | 126 866 (67) | 568 (51) | 308 (48) | 306 (67) | 118 839 (68) |
| Unknown | 15 (1) | 13 886 (7) | 8 (1) | 7 (1) | 8 (2) | 11 164 (6) |
| CCI | ||||||
| 0 | 828 (46) | 130 851 (69) | 537 (47) | 291 (45) | 365 (80) | 121 005 (70) |
| 1 | 342 (19) | 30 055 (16) | 250 (22) | 92 (14) | 69 (15) | 27 828 (16) |
| 2 | 205 (11) | 12 426 (7) | 133 (12) | 72 (11) | 16 (3) | 11 382 (7) |
| ≥3 | 410 (23) | 16 019 (8) | 219 (19) | 191 (30) | 9 (2) | 13 706 (8) |
| Calendar period in 2020 | ||||||
| March–June | 454 (25) | 23 553 (12) | 277 (24) | 177 (27) | 69 (15) | 20 668 (12) |
| July–September | 447 (25) | 47 027 (25) | 289 (25) | 158 (24) | 117 (25) | 42 966 (25) |
| October–December | 884 (50) | 118 771 (63) | 573 (50) | 311 (48) | 273 (59) | 110 287 (63) |
| ART use in past 12 mo | ||||||
| Yes | 1540 (86) | … | 1139 (100) | 401 (62) | … | … |
| No | 245 (14) | … | 0 (0) | 245 (38) | … | … |
| CD4 cell count | ||||||
| < 200/µL | 199 (11) | … | 92 (8) | 107 (17) | … | … |
| 200–499/µL | 389 (22) | … | 246 (22) | 145 (22) | … | … |
| ≥ 500/µL | 906 (51) | … | 665 (58) | 241 (37) | … | … |
| Unknown | 291 (16) | … | 136 (12) | 155 (24) | … | … |
| HIV RNA, copies/mL | ||||||
| < 75 | 1342 (75) | … | 942 (83) | 400 (62) | … | … |
| 75–499 | 80 (4) | … | 54 (5) | 26 (4) | … | … |
| ≥500 | 60 (3) | … | 32 (3) | 28 (4) | … | … |
| Unknown | 303 (17) | … | 111 (10) | 192 (30) | … | … |
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CCI, Charlson comorbidity index; HIV, human immunodeficiency virus; PrEP, preexposure prophylaxis; PWH, people with HIV; PWoH, people without HIV.
Differences were significant for all variables by χ2 test (P < .001).
Subset limited to Kaiser Permanente Northern California, Kaiser Permanente Mid-Atlantic States, and Vanderbilt Comprehensive Care Clinic HIV Cohort.
BMI calculated as weight in kilograms divided by height in meters squared.